Neuropace/$NPCE

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Neuropace

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.

Ticker

$NPCE
Sector
Primary listing

Employees

209

Neuropace Metrics

BasicAdvanced
$326M
-
-$0.84
1.90
-

What the Analysts think about Neuropace

Analyst ratings (Buy, Hold, Sell) for Neuropace stock.

Bulls say / Bears say

NeuroPace reported record Q2 2025 revenue of $23.5 million, representing 22% year-over-year growth driven by increased RNS System sales (GlobeNewswire )(Investing.com)
The company’s gross margin improved to 77.1% in Q2 2025 from 73.4% in Q2 2024, reflecting manufacturing efficiencies and a favorable product mix (GlobeNewswire )(Investing.com)
Three-year Post-Approval Study data showed an 82% median reduction in seizures at three years, underscoring the long-term efficacy of the RNS System in drug-resistant focal epilepsy (GlobeNewswire )(Investing.com)
NeuroPace reported a net loss of $8.7 million in Q2 2025, widening from $7.5 million in the year-ago quarter, indicating continued unprofitability (GlobeNewswire )(Investing.com)
Cash, cash equivalents, and short-term investments declined to $62.1 million at June 30, 2025, down from $66.3 million at the end of Q1 2025, tightening the company’s financial runway (GlobeNewswire)
Preliminary one-year data from the NAUTILUS study for idiopathic generalized epilepsy did not meet its primary effectiveness endpoint, potentially delaying FDA expansion into the IGE indication (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2025.

Neuropace Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Neuropace Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NPCE

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs